Loder 总体耐受性良好 • 第 2 期 PoC c 临床试验研究人员报告说，Loder 治疗耐受性良好；安全事件主要与手术有关 — 肿瘤内通过内窥镜检查 (EUS) 给予延释siRNA • N o 治疗导致研究中止或死亡的紧急不良事件 (TEAE)，报告了与洛德治疗相关的任何生命体征参数或体格检查结果研究报告 • 独立药物安全监督委员会（DSMB）的审查没有安全问题或安全限制 • 在子集分析中，未检测到可测量数量的 Loder（
SIL-204 KRAS G12D/V 和 KRAS 扩增 siRNA 配方
利用 Loder 临床数据进一步提高 SIL-204 潜在疗效和安全性*EUS 内窥镜检查是一项标准程序，用于每 3 个月进行一次超声引导活检。SIL-204 LODER `KRAS G12D/V+ KRAS 放大 KRAS G12D/V siRNA 靶标添加疏水铅以增加 siRNA 进入细胞内和细胞内部的途径没有疏水性导线进入肿瘤细胞的作用部位> 48 小时
SIL-204 抑制小鼠体内人类胰腺癌异种移植的生长 • p

SIL-204 在人体血清中体外稳定超过 48 小时 siRNA 链置于人体血清中并经过稳定性测试人体血清中 siRNA 链的稳定性 siRNA 的潜在效果更长 siRNA 在整个纤维肿瘤环境中的扩散能力更强其他适应症的潜力 0% 20% 30% 50% 60% 70% 90% 100% 0 1 2 4 6 14 24 48% 完整的 SIRNA GUIDE CHRAND LODER SIL-204 18 先前的研究表明 sig12D (Loder) 半衰期在人体血清中为 500万.n。

SIL-204 在大鼠体内稳定五小时 19 1.吉夫拉里（givorisan）。埃玛。2.Alnylam。Givosiran NDA 多学科审查。3.卢马西兰。评论 (fda.gov)。4.卢马西兰。印第安纳州莱克维奥——inclisiran (europa.eu)。5.Inclisiran。印第安纳州莱克维奥——inclisiran (europa.eu)。6.Inclisiran EMA 评估报告。7.Vutrisiran。美国食品和药物管理局审查摘要。8.EMA/FDA 批准的 siRNA 药物：ADME 研究概述和数据解释。siRNA 的有效性更长 siRNA 在整个纤维肿瘤环境中的扩散能力更强其他适应症的潜力 0 1 2 3 4 5 6 7 8 9 10 SIL-204 Givosiran Lumasiran Inclisiran Inclisiran Vutrisiran Hour SIRNA SIRNA 半衰期 SIRNA 在大鼠和人体血浆中的半衰期（不是头对头比较）大鼠的半衰期——人类的寿命可能比大鼠1-8岁高4至6倍 SIL-204 可能是最稳定的 siRNA

SIL-204 LAPC 2023 H1 2024 H1 2025 H 2 2025 H2 2025 H1 2026 LAPC Loder 在 FDA 各方面优化 siRNA 的可批准终点中进行临床概念验证；选择 SIL-204 采用新的延期发布配方收到德国联邦药品和医疗器械研究所 (bFarm) 的试验设计指导启动毒理学研究 SIL-204 启动 GMP 生产最终配方 SIL-204 在欧盟提交针对局部晚期胰腺患者的 SIL-204 第 2/3 期启动 SIL-204 的 CTA欧盟20中的癌症表示活动已完成。未标记的待执行活动。

LAPC的SIL-204的第二/三阶段试验：拟议的研究设计得到了德国监管机构对建议的试验设计的积极指导。第 1 组：SIL-2040+ SOC Chemo Arm 2：SOC Chemo 研究结束第 1 天，2:1 随机化 dsMB ~ 15 名受试者出于安全考虑，1 个月后FU 如果胰腺切除术后 FU 治疗化疗运行-中期分析 ~1/3 个事件 P2→P3 Go/No-Go-Go 筛查 28 天每位患者治疗期 24 个月或直到死亡或肿瘤太小无法治疗长期延期试验 5 年随机化疗运行——第 2 阶段安全运行——第 2 阶段扩展第 3 阶段 21

世界——著名专家科学顾问委员会艾琳·奥赖利医学博士纪念馆纽约州斯隆·凯特琳温思罗普·洛克菲勒基金会肿瘤内科主席；大卫·鲁宾斯坦胰腺癌研究中心医疗计划联合主任；德国慕尼黑工业大学Hepatopancreatobi医学博士Hana Algul，肿瘤代谢系主任；综合癌症主任德国慕尼黑中心 Klinikum rechts der Isar，Mildred-Scheel-教授，德克萨斯大学医学博士、安德森癌症医学博士德克萨斯州休斯敦中心癌症医学部胃肠道（GI）肿瘤内科教授 Philip A. Philip，医学博士，密歇根州底特律亨利福特健康中心胃肠道肿瘤学主任；胰腺癌中心联席主任；亨利福特癌症研究所研究和临床护理整合医学主任 Talia Golan，医学博士 Sheba Tel Hashomer 医院，以色列谢巴胰腺癌中心主任-SPCC Katz，MD 德克萨斯大学兼医学博士安德森癌症中心德克萨斯州休斯敦分校肿瘤外科系主任外科和教授。安德鲁·洛伊，医学博士，加州大学圣地亚哥分校外科肿瘤科主任；外科教授 Mark A. Schattner，医学博士，纽约州斯隆·凯特琳纪念医学博士，纽约州胃肠病学、肝病学和营养服务主任 22

经验丰富的领导团队伊兰·哈达尔，工商管理硕士主席兼首席执行官 > 在制药和高科技公司拥有25年的跨国管理和企业经验 Mitchell Shirvan，博士，工商管理硕士首席科学与开发官 > 在生物技术公司拥有25年的研发、创新和发现经验，注册会计师首席财务官米里特·霍伦什泰因·哈达尔 > 在制药和高科技领域的上市公司和私营公司高级财务职位有15年的企业融资经验-科技行业伊兰·莱文，董事辣木收购公司前董事长兼首席执行官，在以色列高科技相关企业中拥有25年的高管和风险投资/私募股权投资经验 23

投资亮点 CTA=临床试验申请；IND=研究性新药。• 临床阶段，拥有专有癌基因 siRNA 平台的公司 • 胰腺癌肿瘤内 siRNA 的递送与系统性 KRAS 抑制剂相比，可获得更好的药物暴露 • 在LAPC进行Loder的2期临床试验显示，FDA批准的总存活终点改善了9.3个月 • 主要候选药物SIL-204，siRNA稳定性增强，延期效果更好-发布简介肿瘤学中的高级 RNA 候选疗法后期准备就绪资产具有潜在的监管前进路径与稳固的知识产权组合建立了牢固的合作伙伴关系 • 德国联邦药品和医疗器械研究所（bFarm）关于2/3期试验的指导意见 • 计划于2025年底在欧盟提交CTA，并于2026年启动SIL-204的2/3期试验 • 建立siRNA和微粒的GMP生产合作伙伴关系 • siRNA和微粒的强大知识产权组合，独家经营至2043年12月并延期

KRAS Oncogene is a Validated Target for Numerous Cancers 5 Prevalence of The Most Common Types of KRAS Mutations Across Cancers CRC=colorectal cancer; LAPC=locally advanced pancreatic cancer; NSCLC=non - small cell lung cancer. Lee, J.K. et al. NPJ Precis Oncol. 2022;6(1):91. PDAC CRC Non - sq NSCLC Small Bowel Adenocarcinoma Appendix KRAS is the most common oncogenic gene driver in human cancers with gastrointestinal cancers having high percentages of KRAS G12D/V mutations % KRAS mutations 92% 49% 35% 53% 61 %

Pancreatic Cancer Has One of the Highest Mortality Rates of All Major Cancers BRPC=borderline resectable pancreatic cancer; LAPC = locally advanced pancreatic cancer. 1. Bray F, et al. CA Cancer J Clin . 2024;74(3):229 - 263. 2. Hirshberg Foundation for Pancreatic Cancer Research. Pancreatic cancer Facts. https:// pancreatic.org /pancreatic - cancer/pancreatic - cancer - facts. 3. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. https:// seer.cancer.gov / statfacts /html/ pancreas.html . 4. Gemenetzis G, et al. Ann Surg . 2019;270(2):340 - 347. 5. Kleeff J, et al. Nat Rev Dis Primers . 2016;2:16022. Local Metastatic At diagnosis: 10 - 20% resectable 30 - 40% LAPC + BRPC 50 - 60 % metastatic or systemic Types and Prevalence of Pancreatic Cancer 4,5 6 There are no effective treatment options for our intended indication LAPC 3 rd leading cause today in the U.S. 2 2 nd leading cause by 2030 2 12.8% 5 - year relative survival (2014 - 2020) is one of the poorest in the U.S. 3 Median overall survival for non - resectable PC populations is 14 - 17 months 4

Treating KRAS the Cancer - Driver at the Source and Site of Action Silexion siRNA technology prevents mutated KRAS from being produced while small molecule inhibitors target the functioning KRAS protein Silencing oncogene at the production stage is potentially more efficient and safe approach to treat cancer and overcome treatment - resistance Mutated KRAS gene Mutated KRAS mRNA Functional mutated KRAS protein Transcription Translation Silexion siRNA KRAS small molecule inhibitors ( Systemic delivery) Intratumor delivery Cell proliferation Migration Transformation Survival 7

Intratumor siRNA Administration is Advantageous to Systemic Delivery in Solid Tumors Especially Pancreatic x May overcome the limitations of systemic delivery, and allow obtaining higher intratumor concentrations, and better exposure throughout the primary tumor x Can potentially lead to lower systemic exposure due to limited escape from tumor after intratumor administration x EUS endoscopy provides access to different tumor locations within the affected organ EUS = endoscopic ultrasound; LAPC = locally advanced pancreatic cancer. Solid tumors, such as LAPC, are characterized by excessive fibrous tissue and low blood supply which limit the ability of systemically - administered drug to: 1) Reach to the tumor and within the tumor microenvironment 2) Obtain a sufficient concentration in the tumor for optimum activity Systemic exposure may lead to increased adverse events Limitations of Systemic Delivery Advantages of Intratumor Delivery

G12D G12V G12C G12A G12R Multiple Other KRAS Demographics KRAS mutations are present in ~92% pancreatic cancer cases 1 LAPC = localized advanced pancreatic cancer; ROW=rest of the world.*Number of KRAS G12D/V mutated LAPC were calculated based on KRAS mutations being present in 92% of pancreatic cancer patients, 70 - 75% with KRAS G12D and G12V mutations and 30 - 35% of cases being LAPC. 1. Lee, J.K. et al. NPJ Precis Oncol. 2022;6( 1):91. 2. Yousef, A. et al. NPJ Precis Oncol . 20024;8(1):27. 3. Global Cancer Observatory. Pancreatic Cancer. 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/13 - pancreas - fact - sheet.pdf. 4. National Cancer Institute. Cancer Stat Facts: Pancreatic Cancer. 2023. https:// seer.cancer.gov / statfacts /html/ pancreas.html . SIL - 204 covers > 74% of KRAS mutations in PDAC 2 KRAS G12C treatment are treating ~1.5% E.U. U.S. 146,477 3 66,400 4 Annual PC cases ~35,000 ~16,000 KRAS - G12D/V mutated LAPC incidence* 9

LODER Phase 2 Trial Data

Phase 2 Trial of Loder Completed in 2023 – a Proof - of - Concept Two - part, open label, study of LODER + SoC chemotherapy vs SoC chemotherapy alone across the U.S. and Israel in patients with non - resectable pancreatic cancer SoC=standard of care. Arm 1: LODER + SOC Chemo (n=18) Day 0 Randomization Long - term follow up Screening Death Determination of eligibility First LODER administration ~7 days later 1 st chemo Week 8 – 1 st CT Arm 2: SOC Chemo (n=11) Every 12 weeks – LODER administration Every 12 weeks – CT Screening Death Determination of eligibility First LODER administration ~7 days later 1 st chemo Week 8 – 1 st CT Arm 2: LODER + SOC Chemo (n=20) Every 12 weeks – LODER administration Every 12 weeks – CT Long - term follow up Cohort 1 (randomized) Cohort 2 (single arm) 11 Key inclusion criteria Non - resectable without signs of metastasis Both cohorts all patients meeting inclusion/exclusion criteria randomized without checking for KRAS mutation status Endpoints Overall survival (OS) Response rate (RR, RECIST v1.1) Safety Tolerability

Baseline Characteristics and Cohorts Information Due to results of a clinical trial indicating FOLFIRINOX’s advantage over GnP as SoC chemotherapy, cohort 2’s SoC chemotherapy was changed from GnP (used in cohort 1) to FOLFIRINOX. *KRAS mutations were determined in 31 patients in total. In cohort 1 , 12 patients in the treatment arm and 10 patients in the control arm were tested; in cohort 1 , 9 patients were tested. BRPC=borderline resectable pancreatic cancer; GnP =gemcitabine/nab - paclitaxel; LAPC=locally advanced pancreatic cancer; SoC=standard - of - care. Cohort 2 (n=20) Cohort 1 (n=29) Single arm Randomized, controlled (SoC) Design/Arms Non - resectable (BRPC+ LAPC) Locally advanced PC (LAPC) Population 62% U .S. ( 4 sites) , 38% Israel (5 sites) Nationality 42% male; 58% female Male/ Female % 64.9 69.7 Median age (years) G12D/V*: Loder 7/9 G12R*: Loder: 2/9 G12D/V*: Loder 11/12, Control 5/10 G12R*: Loder: 1/12, Control 5/10 KRAS Mutations 2.1 2.8 Avg Loder cycles 370 Total number of Loder injections (modified) FOLFIRINOX ((m)FFX) gemcitabine/nab - paclitaxel ( GnP ) SoC chemotherapy 12

Cohort 1 Patients Treated with Loder Bearing KRAS G12D/V Mutation Had 9.3 Months Improvement in Overall Survival 13 * SoC (Control) OS consistent with recent trials for LAPC ( Gemenetzis G, et al. Ann Surg. 2019;270(2):340 - 347). • A subgroup of subjects with the D or V KRAS mutation, the median OS was 691 days for 11 Loder - treated subjects compared to 409 days for 5 SoC subjects • Not powered for statistical significance • Although the primary endpoints of all patients were not met, the results showed a trend for differences between treatment groups in patients with the KRAS G12D/V mutation, with the Loder arm suggesting an overall survival advantage of 9.3 months Days OS in Cohort 1 SOC chemo median = 13.4 mo .* siRNA+SOC chemo median= 22.7 mo .

Loder Was Overall Well Tolerated • The Phase 2 PoC c linical trial investigators reported that Loder treatment was well tolerated; Safety events were primarily related to procedure – Intratumor administration of extended - release siRNA via endoscopy (EUS) • N o Treatment Emergent Adverse Events (TEAEs) leading to study discontinuation nor deaths related to Loder treatment reported • No meaningful observations in any vital sign parameter nor any physical examination findings in the study reported • Independent Drug Safety Monitoring Board (DSMB) Reviews had no safety concerns nor safety restrictions • In a subset analysis, no measurable amount of Loder was detected (

SIL - 204 KRAS G12D/V and KRAS amplification siRNA formulation

Leveraging Loder Clinical Data to Further Improve SIL - 204 Potential Efficacy and Safety *EUS endoscopy is a standard procedure used to obtain ultrasound guided biopsies once every 3 months . SIL - 204 LODER ` KRAS G12D/V+ KRAS amplify KRAS G12D/V siRNA target Added hydrophobic lead to increase siRNA access to - and within - the cell No hydrophobic lead Access to tumor cell site of action > 48 hrs

SIL - 204 Inhibited Human Pancreatic Cancer Xenograft Growth in Mice • p

SIL - 204 is Stable In Vitro for Over 48 Hours in Human Serum siRNA strand placed in human serum and tested for stability Stability of siRNA Strand in Human Serum Potential longer effectiveness of siRNA Greater ability to diffuse throughout the fibrous tumor environment Potential in other indications 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 1 2 4 6 14 24 48 % OF INTACT SIRNA GUIDE STRAND HOURS LODER SIL-204 18 Previous studies have shown siG12D (Loder) half - life to be 5 min in human serum.

SIL - 204 is Stable In Vivo in Rats for Five Hours 19 1. Givlaari ( givorisan ). EMA. 2. Alnylam. Givosiran NDA MULTI - DISCIPLINE REVIEW. 3. Lumasiran . Review ( fda.gov ). 4. Lumasiran . Leqvio , INN - inclisiran ( europa.eu ) . 5. Inclisiran . Leqvio , INN - inclisiran ( europa.eu ). 6. Inclisiran EMA Assessment Report. 7. Vutrisiran . FDA Review Summary. 8. EMA/FDA Approved siRNA Drugs: ADME Study Overview and Data Interpretation. Longer effectiveness of siRNA Greater ability to diffuse throughout the fibrous tumor environment Potential in other indications 0 1 2 3 4 5 6 7 8 9 10 SIL-204 Givosiran Lumasiran Inclisiran Vutrisiran Hour SIRNA siRNA Half - Life in Rats and Human Plasma (not a head - to - head comparison) Rat Human siRNA half - life in humans is 4 - 6x higher than in rats 1 - 8 potentially suggesting SIL - 204 may be the most stable siRNA

SIL - 204 Development Strategy in LAPC 2023 H1 2024 H 1 2025 H 2 2025 H1 2026 Clinical proof of concept for Loder in LAPC in an approvable endpoint for FDA Optimization of siRNA on various fronts; selection of SIL - 204 with new extended - release formulation Received guidance on trial design from the German Federal Institute for Drugs and Medical Devices ( BfArM ) Initiate toxicology studies SIL - 204 Initiate GMP production final formulation SIL - 204 Submit CTA in E.U. for Phase 2/3 Initiate Phase 2 / 3 of SIL - 204 in patients with locally advance pancreatic cancer in E.U. 20 Indicates completed activity. Unmarked activities to be performed.

Phase 2 / 3 Trial of SIL - 204 in LAPC: Proposed Study Design Received positive guidance from German regulatory agency on suggested trial design. Arm 1: SIL - 204B + SOC Chemo Arm 2 : SOC Chemo End of Study Day 1 , 2:1 Randomization DSMB ~ 15 subjects for safety following 1 mo. FU If pancreatectomy Post Surgery FU Treatment Chemo run - in Interim Analysis ~1/3 events P2→P3 Go/No - Go Screening 28d Death Each Patient Treatment Period 24 months or until death or the tumor is too small to treat Long Term Extension Trial for overall survival 5 yrs from randomization Chemo run - in Phase 2 Safety run - in Phase 2 expanded Phase 3 21

World - Renowned Expert Scientific Advisory Board Eileen M. O'Reilly, MD Memorial Sloan Kettering, NY, NY Winthrop Rockefeller Endowed Chair of Medical Oncology; Co - Director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research; Section Head, Hepatopancreatobi Hana Algul , MD Technical University of Munich, Germany chair for tumor metabolism; Director of the Comprehensive Cancer Center Munich, Germany at the Klinikum rechts der Isar, and Mildred - Scheel - professor and Milind Javle , MD The University of Texas & MD Anderson Cancer Center, Houston, TX Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine Philip A. Philip, MD Henry Ford Health, Detroit, MI Director, Gastrointestinal Oncology; Co - Director, Pancreatic Cancer Center; Medical Director, Research and Clinical Care Integration, Henry Ford Cancer Institute Talia Golan, MD Sheba Tel Hashomer Hospital,, Israel Head, Sheba Pancreatic Cancer Center - SPCC Matthew Katz, MD The University of Texas & MD Anderson Cancer Center, Houston, TX Department Chair, Department of Surgical Oncology, Division of Surgery and Professor. Andrew M. Lowy, MD UC San Diego, San Diego, CA Chief, Division of Surgical Oncology; Professor of Surgery Mark A. Schattner , MD Memorial Sloan Kettering, NY, NY Chief, Gastroenterology, Hepatology and Nutrition Service 22

Highly Experienced Leadership Team Ilan Hadar , MBA Chairman and Chief Executive Officer > 25 years of multinational managerial and corporate experience with pharmaceutical and high - tech companies Mitchell Shirvan, PhD, MBA Chief Scientific and Development Officer > 25 years of experience in R&D, innovation and discovery in biotech companies Mirit Horenshtein Hadar, CPA Chief Financial Officer > 15 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high - tech industries Ilan Levin, Director Former Chairman & Chief Executive Officer of Moringa Acquisition Corp with 25 years of experience as an executive and venture capital/private equity investor in high - tech, Israel - related ventures 23

Investment Highlights CTA=clinical trial application; IND=investigational new drug. • Clinical - stage company with proprietary oncogene siRNA platform • Intratumor siRNA delivery for pancreatic cancer allow for better drug exposure compared with systemic KRAS inhibitors • Phase 2 clinical trial with Loder in LAPC showed 9.3 months improvement in the FDA approvable endpoint of overall survival • Lead Candidate SIL - 204 with enhanced siRNA stability, and a better extended - release profile Advanced RNA therapeutic candidate in oncology Late - Stage Ready Asset with Potential Regulatory Path Forward Strong Partnerships with Solid IP Portfolio • Guidance received from German Federal Institute for Drugs and Medical Devices ( BfArM ) on Phase 2 / 3 trial • Plans to submit CTA in E.U. late 2025 and initiate Phase 2 / 3 trial of SIL - 204 in 2026 • Established partnerships for GMP production of siRNA and delivery system • Strong IP portfolio for siRNA and microparticles with exclusivity through December 2043 with extension